Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 8
Submit an article Journal homepage
887
Views
11
CrossRef citations to date
0
Altmetric
Review

Anti-diabetic drugs and NASH: from current options to promising perspectives

Sarra Smatia Department of Endocrinology, Université De Nantes, CHU Nantes, CNRS, INSERM, L’institut Du Thorax, Nantes, France
,
Clémence M Canivetb Hepato-Gastroenterology department, University Hospital, Angers, France;c HIFIH Laboratory, EA 3859, University of Angers, Angers, France
,
Jérôme Boursierb Hepato-Gastroenterology department, University Hospital, Angers, France;c HIFIH Laboratory, EA 3859, University of Angers, Angers, France
&
Bertrand Carioua Department of Endocrinology, Université De Nantes, CHU Nantes, CNRS, INSERM, L’institut Du Thorax, Nantes, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1580-8040
ORCID Icon
Pages 813-825 | Received 27 Apr 2021, Accepted 01 Jul 2021, Published online: 12 Jul 2021

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

André J. Scheen. (2023) Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update. Expert Opinion on Drug Metabolism & Toxicology 19:8, pages 543-553.
Read now
Acharya Balkrishna, Vivek Gohel, Priya Kumari, Moumita Manik, Kunal Bhattacharya, Rishabh Dev & Anurag Varshney. (2022) Livogrit Prevents Methionine-Cystine Deficiency Induced Nonalcoholic Steatohepatitis by Modulation of Steatosis and Oxidative Stress in Human Hepatocyte-Derived Spheroid and in Primary Rat Hepatocytes. Bioengineered 13:4, pages 10811-10826.
Read now

Articles from other publishers (9)

Raluca Pais, Bertrand Cariou, Mazen Noureddin, Sven Francque, Jörn M. Schattenberg, Manal F. Abdelmalek, Gadi Lalazar, Sharat Varma, Julie Dietrich, Veronica Miller, Arun Sanyal & Vlad Ratziu. (2023) A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. Journal of Hepatology 79:3, pages 829-841.
Crossref
Mingning Ding, Fei Zhou, Yijie Li, Chuanyang Liu, Yiqing Gu, Jianzhi Wu, Guifang Fan, Yajing Li & Xiaojiaoyang Li. (2023) Cassiae Semen improves non-alcoholic fatty liver disease through autophagy-related pathway. Chinese Herbal Medicines 15:3, pages 421-429.
Crossref
Sarra Smati, Clémence M. Canivet, Jérôme Boursier & Bertrand Cariou. (2023) Voies thérapeutiques dans l’hépatopathie stéatosique métabolique. Médecine des Maladies Métaboliques.
Crossref
Ajay Duseja, S.P. Singh, Arka De, Kaushal Madan, Padaki Nagaraja Rao, Akash Shukla, Gourdas Choudhuri, Sanjiv Saigal, Shalimar, Anil Arora, Anil C. Anand, Ashim Das, Ashish Kumar, Chundamannil E. Eapen, Krishnadas Devadas, Kotacherry T. Shenoy, Manas Panigrahi, Manav Wadhawan, Manish Rathi, Manoj Kumar, Narendra S. Choudhary, Neeraj Saraf, Preetam Nath, Sanjib Kar, Seema Alam, Samir Shah, Sandeep Nijhawan, Subrat K. Acharya, Vinayak Aggarwal, Vivek A. Saraswat & Yogesh K. Chawla. (2023) Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Clinical and Experimental Hepatology 13:2, pages 273-302.
Crossref
Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne & Ming-Hua Zheng. (2022) Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clinical and Molecular Hepatology 28:4, pages 725-738.
Crossref
Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou & Ioannis S. Vizirianakis. (2022) Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 11:6, pages 1060.
Crossref
Marija Branković, Igor Jovanović, Marija Dukić, Tijana Radonjić, Svetlana Oprić, Slobodan Klašnja & Marija Zdravković. (2022) Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences 23:9, pages 5146.
Crossref
Bertrand Cariou. (2022) The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes, Obesity and Metabolism 24:S2, pages 15-27.
Crossref
红红 李. (2022) Progress in the Treatment of Metabolism-Related Fatty Liver Disease. Advances in Clinical Medicine 12:09, pages 8647-8654.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.